18.98

3.66% 0.67

After Hours: 19.05 0.07 +0.37%

Summit Therapeutics Inc (SMMT)

Overview News Price History Option Chain Financials Why SMMT Down? Discussions Forecast

Summit Therapeutics Inc stock is traded at $18.98, with a volume of 1.39M. It is up +3.66% in the last 24 hours and down -10.51% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Previous Close:

$18.31

Open:

$18.36

24h Volume:

1.39M

Relative Volume:

0.28

Market Cap:

$14.00B

Revenue:

$956.00K

Net Income/Loss:

$-196.68M

P/E Ratio:

-11.29

EPS:

-1.6811

Net Cash Flow:

$-113.02M

1W Performance:

-12.82%

1M Performance:

-10.51%

6M Performance:

+327.48%

1Y Performance:

+883.42%

1-Day Range:

$18.11

$19.25

1-Week Range:

$18.11

$22.25

52-Week Range:

$1.89

$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name

Summit Therapeutics Inc

Sector

Healthcare (1204)

Industry

Biotechnology (683)

Phone

305-203-2034

Address

601 BRICKELL KEY DRIVE, MIAMI

Employee

105

Twitter

@summitplc

Next Earnings Date

2024-10-30

Latest SEC Filings

SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SMMT	18.98	14.00B	956.00K	-196.68M	-113.02M	-1.6811
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy
Feb-13-18	Initiated	BTIG Research	Buy
Jan-04-18	Initiated	SunTrust	Buy
Dec-01-17	Resumed	H.C. Wainwright	Buy
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform
Oct-05-16	Reiterated	Needham	Buy
Sep-16-16	Initiated	H.C. Wainwright	Buy
Mar-30-15	Initiated	Needham	Buy
Mar-30-15	Initiated	Oppenheimer	Outperform

View All

Summit Therapeutics Inc Stock (SMMT) Latest News

08:32 AM

Summit Therapeutics' (SMMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

08:32 AM

Nov 17, 2024

(SMMT) Trading Report - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

Here's Merck's $3.3 Billion Insurance Against Summit's Advance - Investor's Business Daily

Nov 14, 2024

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters

Nov 14, 2024

Nov 13, 2024

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga

Nov 09, 2024

Is Summit Therapeutics a Millionaire Maker? - AOL

Nov 09, 2024

Nov 08, 2024

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 08, 2024

Why Summit Therapeutics Stock Was a Winner Today - MSN

Nov 08, 2024

Nov 06, 2024

Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily

Nov 06, 2024

Nov 04, 2024

SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com

Nov 04, 2024

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN

Nov 04, 2024

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK

Nov 04, 2024

Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com

Nov 04, 2024

Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK

Nov 04, 2024

Summit Therapeutics Leads The Parade Of Big Gainers - Forbes

Nov 04, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat

Nov 04, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN

Nov 04, 2024

Nov 03, 2024

3 Magnificent Stocks Under $100 to Buy in November - The Motley Fool

Nov 03, 2024

Nov 01, 2024

abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Nov 01, 2024

Oct 31, 2024

H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada

Oct 31, 2024